Glaukos (NYSE:GKOS) Posts Earnings Results, Beats Expectations By $0.07 EPS

Glaukos (NYSE:GKOS) issued its quarterly earnings data on Wednesday. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.07, FiscalAI reports. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.The company had revenue of $185.61 million during the quarter, compared to analysts’ expectations of $150.93 million. During the same quarter in the previous year, the company posted ($0.24) earnings per share. The business’s revenue was up 49.6% on a year-over-year basis.

Here are the key takeaways from Glaukos’ conference call:

• Record second-quarter sales reached $185.6 million, up 50% year over year, prompting Glaukos to raise full-year 2026 revenue guidance to $680 million–$700 million from $620 million–$635 million.
• U.S. glaucoma sales rose 64% to $118.5 million, with iDose TR contributing approximately $74 million. Management expects iDose TR revenue of roughly $275 million–$280 million for 2026, supported by expanding surgeon adoption and commercial and Medicare Advantage utilization.
• Epioxa generated approximately $11 million in its first full commercial quarter, while the broader corneal health franchise is now expected to grow about 20% year over year in 2026. The company reported treatment-center coverage reaching roughly 85% of the U.S. population and payer access covering more than 125 million commercial lives.
• The transition from Photrexa and a miscellaneous billing code to Epioxa’s permanent J-code is expected to create volatility or a temporary “air pocket” in third-quarter corneal revenue, with improvement anticipated in the fourth quarter and into 2027.
• Potential Medicare coverage restrictions for iDose TR remain an important uncertainty, as proposed local coverage determinations from five of seven Medicare Administrative Contractors include criteria the company opposes. International glaucoma growth may also face competitive trialing, reimbursement pressure in Germany and Switzerland, and fading foreign-exchange tailwinds.

Glaukos Price Performance

Shares of Glaukos stock traded up $10.64 during trading on Wednesday, reaching $161.97. 3,136,767 shares of the company’s stock were exchanged, compared to its average volume of 634,278. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.43 and a quick ratio of 4.73. Glaukos has a 1-year low of $73.16 and a 1-year high of $166.00. The firm’s 50-day moving average price is $136.63 and its 200 day moving average price is $124.40.

Insider Activity at Glaukos

In other Glaukos news, CFO Alex R. Thurman sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 16th. The shares were sold at an average price of $160.00, for a total value of $1,600,000.00. Following the sale, the chief financial officer owned 43,906 shares in the company, valued at $7,024,960. This trade represents a 18.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Leana Wen sold 1,700 shares of the company’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $143.35, for a total transaction of $243,695.00. Following the transaction, the director owned 19,739 shares of the company’s stock, valued at $2,829,585.65. This trade represents a 7.93% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 71,273 shares of company stock valued at $10,482,003. 5.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Glaukos

A number of institutional investors and hedge funds have recently bought and sold shares of GKOS. Hsbc Holdings PLC acquired a new position in shares of Glaukos in the fourth quarter valued at approximately $209,000. Invesco Ltd. increased its position in Glaukos by 28.5% in the 4th quarter. Invesco Ltd. now owns 780,267 shares of the medical instruments supplier’s stock valued at $88,100,000 after acquiring an additional 172,825 shares during the period. Corient Private Wealth LLC increased its position in Glaukos by 999.3% in the 4th quarter. Corient Private Wealth LLC now owns 30,978 shares of the medical instruments supplier’s stock valued at $3,498,000 after acquiring an additional 28,160 shares during the period. Summit Global Investments raised its stake in shares of Glaukos by 151.3% during the fourth quarter. Summit Global Investments now owns 7,052 shares of the medical instruments supplier’s stock valued at $796,000 after acquiring an additional 4,246 shares during the last quarter. Finally, Mackenzie Financial Corp raised its stake in shares of Glaukos by 331.8% during the fourth quarter. Mackenzie Financial Corp now owns 15,404 shares of the medical instruments supplier’s stock valued at $1,756,000 after acquiring an additional 11,837 shares during the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on GKOS shares. BTIG Research restated a “buy” rating and issued a $164.00 price target on shares of Glaukos in a research note on Monday, July 13th. Citigroup increased their price objective on Glaukos from $162.00 to $175.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. JPMorgan Chase & Co. lifted their target price on Glaukos from $120.00 to $140.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. Wells Fargo & Company boosted their target price on shares of Glaukos from $135.00 to $138.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Finally, William Blair reaffirmed an “outperform” rating on shares of Glaukos in a research report on Tuesday, May 26th. Twelve investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Glaukos presently has an average rating of “Moderate Buy” and a consensus target price of $155.23.

Key Stories Impacting Glaukos

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Revenue significantly exceeded expectations: Q2 2026 revenue reached $185.6 million, up approximately 50% year over year and well above the $150.9 million analyst consensus. Gross profit rose to $151.6 million, signaling strong demand and improved sales momentum. Glaukos Announces Second Quarter 2026 Financial Results
• Positive Sentiment: Raised revenue outlook: Glaukos guided to fiscal 2026 revenue of $680 million to $700 million, well above the roughly $630 million consensus estimate. The company also reported adjusted quarterly EPS of negative $0.14, better than the expected negative $0.21.
• Positive Sentiment: Pipeline progress: Enrollment has been completed in the pivotal PRESERFLO MicroShunt trial for treatment-resistant glaucoma, an important step toward potential regulatory and commercial expansion. Glaukos completes enrollment in Preserflo MicroShunt study
• Neutral Sentiment: Analyst views remain broadly favorable but mixed: Recent targets include $175 from Citi, $168 from HC Wainwright and $165 from Piper Sandler, while UBS initiated coverage with a neutral rating and a $150 target. The median recent target is approximately $162.
• Negative Sentiment: Profitability remains a concern: Glaukos posted an operating loss of $17.3 million and a net loss attributable to common shareholders of $18.4 million. Operating cash flow was negative $12.5 million, underscoring continued cash-burn risk despite higher revenue.
• Negative Sentiment: Insider selling could weigh on sentiment: The CFO sold 10,000 shares for $1.6 million under a pre-arranged Rule 10b5-1 plan. Quiver data also shows 24 insider sales and no purchases over the past six months, although these transactions may be scheduled rather than discretionary. Glaukos CFO stock sale

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.